Details for New Drug Application (NDA): 210875

✉ Email this page to a colleague

NDA 210875 describes KYNMOBI, which is a drug marketed by Sumitomo Pharma Am and is included in one NDA. There are fourteen patents protecting this drug. Additional details are available on the KYNMOBI profile page.

The generic ingredient in KYNMOBI is apomorphine hydrochloride. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the apomorphine hydrochloride profile page.

Summary for 210875

Tradename:	KYNMOBI
Applicant:	Sumitomo Pharma Am
Ingredient:	apomorphine hydrochloride
Patents:	14

Medical Subject Heading (MeSH) Categories for 210875

Dopamine Agonists
Emetics

Profile for product number 001

Active Rx/OTC/Discontinued:	DISCN	Dosage:	FILM;SUBLINGUAL			Strength	10MG
Approval Date:	May 21, 2020	TE:		RLD:	Yes
Patent:	10,420,763	Patent Expiration:	Jun 11, 2030	Product Flag?	Y	Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE
Patent:	10,449,146	Patent Expiration:	Apr 19, 2036	Product Flag?		Substance Flag?		Delist Request?
Patented Use:	TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE
Patent:	10,821,074	Patent Expiration:	Aug 7, 2029	Product Flag?	Y	Substance Flag?		Delist Request?

Expired US Patents for NDA 210875

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-005	May 21, 2020	8,603,514	⤷ Subscribe
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-001	May 21, 2020	9,855,221	⤷ Subscribe
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-002	May 21, 2020	8,663,687	⤷ Subscribe
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-005	May 21, 2020	11,077,068	⤷ Subscribe
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-003	May 21, 2020	11,077,068	⤷ Subscribe
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.